公开(公告)号：US20240316168A1

公开(公告)日：2024-09-26

申请号：US18586621

申请日：2024-02-26

申请人： Phaim Pharma Ltd.

发明人： Tihamer ORBAN ,  Jalahej HEYMAN ,  Nara DAUBENEY ,  Piers DAUBENEY

IPC分类号： A61K39/00 ,  A61K38/28 ,  A61K45/06 ,  A61P3/10 ,  A61P5/50 ,  A61P37/02 ,  C07K14/00 ,  C07K14/47 ,  C07K14/62 ,  G01N33/68

CPC分类号： A61K39/0005 ,  A61K38/28 ,  A61K39/0008 ,  A61K45/06 ,  A61P3/10 ,  A61P5/50 ,  A61P37/02 ,  C07K14/001 ,  C07K14/4713 ,  C07K14/62 ,  G01N33/6893 ,  A61K2039/55 ,  A61K2039/55505 ,  A61K2039/55511 ,  A61K2039/55566 ,  A61K2039/55588 ,  A61K2039/57 ,  G01N2800/42

摘要： A composition for treating type 1 diabetes mellitus autoimmunity can include a therapeutically effective amount of two or more overlapping fragments of preproinsulin and a pharmaceutically acceptable carrier, wherein at least one of the polypeptide fragments is antigenic.

公开(公告)号：US20240361217A1

公开(公告)日：2024-10-31

申请号：US18770727

申请日：2024-07-12

申请人： Phaim Pharma Ltd.

发明人： Tihamer ORBAN ,  Jalahej HEYMAN ,  Nara DAUBENEY ,  Piers DAUBENEY

IPC分类号： G01N1/40 ,  A61K35/17 ,  A61P17/06 ,  A61P37/06 ,  C12N5/0783 ,  C12Q1/02 ,  G01N1/06 ,  G01N1/28 ,  G01N1/36 ,  G01N1/42 ,  G01N33/50

CPC分类号： G01N1/4077 ,  A61K35/17 ,  A61P17/06 ,  A61P37/06 ,  C12N5/0636 ,  C12Q1/02 ,  G01N1/06 ,  G01N1/2813 ,  G01N1/286 ,  G01N1/36 ,  G01N1/42 ,  G01N33/505 ,  G01N33/5091 ,  G01N2001/2873 ,  G01N2800/24 ,  G01N2800/56

摘要： Provided are methods of preparing an immune cell sample from a subject having an autoimmune disorder, the method comprising: obtaining a tissue sample from the subject; and isolating a single immune cell in situ from the tissue sample using laser capture microdissection.

公开(公告)号：US20240058442A1

公开(公告)日：2024-02-22

申请号：US18183465

申请日：2023-03-14

申请人： Phaim Pharma Ltd.

发明人： Tihamer ORBAN

IPC分类号： A61K39/395 ,  A61K38/17 ,  A61K45/06 ,  G01N33/50 ,  A61K38/28 ,  A61K39/00 ,  C07K14/47 ,  C07K14/62 ,  C07K14/705

CPC分类号： A61K39/3955 ,  A61K38/1774 ,  A61K45/06 ,  G01N33/5094 ,  A61K38/28 ,  A61K39/0008 ,  C07K14/4713 ,  C07K14/62 ,  C07K14/70521 ,  A61K2039/55566 ,  C07K2319/00 ,  C07K2319/30

摘要： A method of treating, preventing, or delaying the progression of Type 1 diabetes mellitus by administering an effective amount of a fusion protein composition comprising a T-cell co-stimulation antagonist and a portion of an immunoglobulin molecule and an effective amount of a Type 1 diabetes autoantigen. The method includes, for example, administering a cytotoxic T-lymphocyte-associated antigen 4 (CTLA4) molecule and a Type 1 diabetes autoantigen. Pharmaceutical compositions are also provided herewith.

公开(公告)号：US20240285732A1

公开(公告)日：2024-08-29

申请号：US18571294

申请日：2022-06-16

申请人： PHAIM PHARMA LTD.

发明人： Tihamer ORBAN ,  Jalahej HEYMAN ,  Nara DAUBENEY ,  Piers DAUBENEY

IPC分类号： A61K38/28 ,  A61M5/00 ,  C12Q1/6883 ,  G01N33/50 ,  G01N33/68

CPC分类号： A61K38/28 ,  A61M5/003 ,  C12Q1/6883 ,  G01N33/505 ,  G01N33/6866 ,  C12Q2600/158 ,  G01N2333/57 ,  G01N2800/042 ,  G01N2800/52

摘要： Compositions of peptide fragments of preproinsulin for the treatment of type 1 diabetes and methods for selecting one or more peptide fragments of preproinsulin suitable for subject-specific immunomodulatory therapy for type 1 diabetes. The one or more peptides may be selected based on an autoimmune phenotype for the subject, which may be characterized by a stimulation assay and/or the based on a genotype for one or more genes related to type 1 diabetes.

公开(公告)号：US20230333094A1

公开(公告)日：2023-10-19

申请号：US18140214

申请日：2023-04-27

申请人： Phaim Pharma Ltd.

发明人： Tihamer ORBAN

IPC分类号： G01N33/50 ,  G01N33/564 ,  G01N33/569

CPC分类号： G01N33/5094 ,  G01N33/564 ,  G01N33/56972 ,  G01N2800/042 ,  G01N2800/52

摘要： A new markers for insulin production decline in Type 1 diabetes has been found in the ratio the CD4 naïve (CD45RO−CD62L+) to central memory (CD45RO+CD62L+) and in the level of CD4 central memory T-cell subpopulations. A method of diagnosing autoimmunity and its progressiveness, more specifically diabetes, pre-diabetes, a susceptibility to diabetes mellitus, or the level of effectiveness of therapy/intervention modality for one or more of such conditions in a subject can be conducted by determining level of CD4 naïve (CD45RO−CD62L+) T-cells by immunofluorescence analysis of a sample extracted from a subject; determining level of CD4 central memory (CD45RO+CD62L+) T-cells by immunofluorescence analysis of a sample extracted from a subject, and quantitatively relating the levels of the CD4 naïve and central memory T-cells, wherein a low ratio of CD4 naïve T-cells to CD4 central memory T-cells and/or high CD4 central memory T-cell indicates autoimmunity, a susceptibility to autoimmunity, diabetes, pre-diabetes, a susceptibility to diabetes mellitus or ineffectiveness of a treatment for one or more of such conditions.